Influence of acetylator phenotype on antidepressant effects of phenelzine.
Acetylator phenotype, determined by blood levels after sulphadimidine, was related to outcome in a controlled trial of phenelzine in patients with depression and mixed anxiety depression. Slow acetylators showed more improvement and greater phenelzine-placebo differences than did fast acetylators, at two, four and six weeks. A tendency towards faster acetylation was observed in subjects with previous increased alcohol intake. Acetylator phenotype was not related to other symptom, diagnostic or history data.
D000107:Acetylation; D001008:Anxiety Disorders / Q000097:blood / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000097:blood / Q000188:drug therapy*; D004311:Double-Blind Method; D006801:Humans; D010624:Phenelzine / Q000627:therapeutic use*; D010641:Phenotype; D013418:Sulfamethazine / Q000097:blood
D013418:Sulfamethazine; D010624:Phenelzine